Lyell Immunopharma, Inc. Stock price

Equities

LYEL

US55083R1041

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-02-23 pm EST 5-day change 1st Jan Change
2.39 USD -2.05% Intraday chart for Lyell Immunopharma, Inc. +28.49% +23.20%
Sales 2023 * 2.1M Sales 2024 * 2.5M Capitalization 602M
Net income 2023 * -240M Net income 2024 * -224M EV / Sales 2023 * 114 x
Net cash position 2023 * 363M Net cash position 2024 * 402M EV / Sales 2024 * 79.8 x
P/E ratio 2023 *
-2.5 x
P/E ratio 2024 *
-2.78 x
Employees 274
Yield 2023 *
-
Yield 2024 *
-
Free-Float 80.93%
More Fundamentals * Assessed data
Dynamic Chart
Phoenix Biotech Acquisition Corp. completed the acquisition of CERo Therapeutics, Inc. CI
MaxCyte's strategic platform licences redeem otherwise modest results AN
Lyell Immunopharma, Inc.(NasdaqGS:LYEL) dropped from S&P Biotechnology Select Industry Index CI
HC Wainwright Trims Lyell Immunopharma's Price Target to $8 From $9, Maintains Buy Rating MT
Earnings Flash (LYEL) LYELL IMMUNOPHARMA Posts Q3 Revenue $25,000 MT
Lyell Immunopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Lyell Immunopharma, Inc. Presents New Nonclinical Data at 38th Annual Meeting of SITC on Innovations Designed to Shorten Tumor Infiltrating Lymphocyte Manufacturing, LYL119 as Well as Data on New Technologies and Design of its Two Clinical Trials in Progress CI
Cellares and Lyell to Evaluate Automated Manufacturing of Lyell's Car T-Cell Therapy on Cellares' Cell Shuttle Platform CI
North American Morning Briefing : Investors Look -2- DJ
JPMorgan Downgrades Lyell Immunopharma to Neutral From Overweight, Adjusts Price Target to $5 From $15 MT
Insider Sell: Lyell Immunopharma MT
Earnings Flash (LYEL) LYELL IMMUNOPHARMA Reports Q2 Revenue $27,000 MT
Lyell Immunopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
MaxCyte Signs Strategic Platform License with Lyell Immunopharma MT
MaxCyte inks strategic platform license with Lyell Immunopharma AN
More news
1 day-2.05%
1 week+28.49%
Current month+30.60%
1 month+13.81%
3 months+38.15%
6 months+7.66%
Current year+23.20%
More quotes
1 week
1.88
Extreme 1.88
2.48
1 month
1.69
Extreme 1.69
2.48
Current year
1.69
Extreme 1.69
2.48
1 year
1.32
Extreme 1.32
3.97
3 years
1.32
Extreme 1.32
19.84
5 years
1.32
Extreme 1.32
19.84
10 years
1.32
Extreme 1.32
19.84
More quotes
Managers TitleAgeSince
Chief Executive Officer 65 21-04-30
Director of Finance/CFO 53 21-01-31
Chief Tech/Sci/R&D Officer 51 20-06-30
Members of the board TitleAgeSince
Chief Executive Officer 65 21-04-30
Director/Board Member 60 18-08-31
Director/Board Member 64 21-03-31
More insiders
Date Price Change Volume
24-02-23 2.39 -2.05% 694,705
24-02-22 2.44 +7.02% 995,627
24-02-21 2.28 +7.55% 1,305,997
24-02-20 2.12 +13.98% 1,314,894
24-02-16 1.86 -2.11% 972,543

Delayed Quote Nasdaq, February 23, 2024 at 04:00 pm EST

More quotes
Lyell Immunopharma, Inc. is a T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors. The technologies powering its product candidates are designed to address barriers that limit consistent and long-lasting responses to cell therapy for solid tumors: T-cell exhaustion and lack of durable stemness, which includes the ability to persist and self-renew to drive durable tumor cytotoxicity. The Company's technologies are designed to generate T cells with the ability to persist and self renew while driving durable tumor cytotoxicity, even in the setting of an immunosuppressive tumor microenvironment. Its technologies can be applied in a target agnostic manner to multiple T cell modalities, including chimeric antigen receptor (CAR), tumor-infiltrating lymphocytes (TIL) and T cell receptor (TCR) therapies. Its product candidates include LYL797, LYL845 and LYL119. The LYL119 is a ROR1 CAR T-cell product designed for enhanced cytotoxicity.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
2.39 USD
Average target price
6.5 USD
Spread / Average Target
+171.97%
Consensus
  1. Stock
  2. Equities
  3. Stock Lyell Immunopharma, Inc. - Nasdaq
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer